KRAS and cancer: The TSG RUNX3 elicits an antitumor activity by regulating the transcription of target genes (p21, c-myc, etc.)of the major cancer signaling cascades, such as transforming growth factor-beta (TGF-β), Wnt/β-catenin, and mitogenic KRAS pathway as explained in Figure 2.